Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 11:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 735 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Ocular Hypertension Glaucoma Clear all
Completed Phase 3 Interventional

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

NCT00051142
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Travoprost, Latanoprost
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2008 · Synced Oct 8, 2026, 11:56 AM EDT
Recruiting Phase 3 Interventional

Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

NCT07495852
View directory record Official record
Conditions
Glaucoma
Interventions
Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure, placebo eye drops
Drug · Procedure · Other
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Dothan, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 8, 2026, 11:56 AM EDT
Completed Not applicable Interventional

Intraocular Pressure Control Following One Site Versus Two Site Combined Phacoemulsification/IOL And Trabeculectomy

NCT00695747
View directory record Official record
Conditions
Glaucoma, Cataracts
Interventions
2 Site procedure- Phacoemulsification/IOL and Trabeculectomy
Procedure
Lead sponsor
Lahey Clinic
Other
Eligibility
Not listed
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2009 · Synced Oct 8, 2026, 11:56 AM EDT
Terminated Not applicable Interventional

Study of the Beacon Aqueous Microshunt in Patients With Refractory Glaucoma

NCT04072016
View directory record Official record
Conditions
Glaucoma
Interventions
Beacon Aqueous Microshunt
Device
Lead sponsor
MicroOptx
Industry
Eligibility
22 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Grand Junction, Colorado • Bloomington, Minnesota • Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Oct 8, 2026, 11:56 AM EDT
Terminated Not applicable Interventional Results available

Comparing Acular LS and Pred Forte in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells

NCT00478036
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Acular LS, Pred Forte, Refresh Tears
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Oct 8, 2026, 11:56 AM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Short-term Effect of Rho-kinase Inhibitor on Retinal Circulation

NCT04234932
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
Netarsudil Ophthalmic
Drug
Lead sponsor
University of the Incarnate Word
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Oct 8, 2026, 11:56 AM EDT
Completed Phase 3 Interventional

GTS400 Stent Implantation in Conjunction With Cataract Surgery in Subjects With Open-angle Glaucoma

NCT01052558
View directory record Official record
Conditions
Glaucoma
Interventions
iStent Inject (GTS400), Cataract Surgery
Device · Procedure
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years to 90 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
22
States / cities
Rogers, Arkansas • Petaluma, California • Parker, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Oct 8, 2026, 11:56 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension

NCT00650338
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
DE-104 ophthalmic solution, low concentration, DE-104 ophthalmic solution, medium concentration, DE-104 ophthalmic solution, high concentration, Placebo, 0.005% latanoprost
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
14
States / cities
Artesia, California • Los Angeles, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2011 · Synced Oct 8, 2026, 11:56 AM EDT
Completed Phase 2 Interventional

AR-12286 in Combination With Latanoprost

NCT01302249
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Latanoprost 0.005%, AR-12286 Ophthalmic Solution 0.5%, Timolol maleate ophthalmic solution 0.5%
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
15
States / cities
New Haven, Connecticut • Roswell, Georgia • Shawnee Mission, Kansas + 11 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Oct 8, 2026, 11:56 AM EDT
Terminated Phase 2 Interventional

The Effectiveness of Ologen® Collagen Matrix in Preventing Intraocular Pressure (IOP) Spikes After Ahmed Glaucoma Valve Surgery (AGV-FP7)

NCT02990143
View directory record Official record
Conditions
Glaucoma
Interventions
Ologen
Procedure
Lead sponsor
The New York Eye & Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Oct 8, 2026, 11:56 AM EDT
Completed Phase 2 Interventional Results available

Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG

NCT02829996
View directory record Official record
Conditions
Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions
trabodenoson 6.0% / latanoprost 0.005% QD, trabodenoson 3.0% / latanoprost 0.005% QD, trabodenoson 6.0% / latanoprost 0.0025% QD, latanoprost 0.005% QD, latanoprost 0.0025% QD
Drug
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Oct 8, 2026, 11:56 AM EDT
Completed Not applicable Interventional

Surgical Treatment of Refractory Open Angle Glaucoma

NCT01212861
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Suprachoroidal Dissection Instrument (SDI)
Device
Lead sponsor
iScience Interventional Corporation
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2012 · Synced Oct 8, 2026, 11:56 AM EDT
Completed Phase 2 Interventional

Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular Pressure

NCT01060579
View directory record Official record
Conditions
Glaucoma
Interventions
AR-12286 0.5% ophthalmic solution, AR-12286 0.25% Ophthalmic solution, Latanoprost ophthalmic solution
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
18
States / cities
Inglewood, California • Petaluma, California • Poway, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Oct 8, 2026, 11:56 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Topical Insulin for Glaucoma (TING2)

NCT07619482
View directory record Official record
Conditions
Open Angle Glaucoma, Primary Open Angle Glaucoma, Low Tension Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma
Interventions
EYED-002 Low Dose (721 U/mL topical insulin), EYED-002 High Dose (1442 U/mL topical insulin), EYED-002 (highest tolerated dose, 12-month), Vehicle Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 90 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 8, 2026, 11:56 AM EDT
Completed Phase 3 Interventional Results available

A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

NCT01830140
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Bimatoprost 0.01%, Bimatoprost 0.03%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Artesia, California • El Paso, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Oct 8, 2026, 11:56 AM EDT
Not listed No phase listed Observational

Comparing Refractive and Visual Outcomes of MIGS and Traditional Surgeries

NCT03584958
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Not listed
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 8, 2026, 11:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Does Lowering Eye Pressure Affect the Results Obtained From Objective Visual Field Testing?

NCT00799994
View directory record Official record
Conditions
Glaucoma
Interventions
Not listed
Lead sponsor
Wills Eye
Other
Eligibility
Not listed
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 8, 2026, 11:56 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Eye Drop Application Monitor, Pilot Study

NCT02639845
View directory record Official record
Conditions
Cataracts, Retina Surgery, Glaucoma, Any Condition That Requires Ophthalmic Drops
Interventions
Not listed
Lead sponsor
Alexander Eaton
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Dec 28, 2015 · Synced Oct 8, 2026, 11:56 AM EDT
Completed Phase 2 Interventional

Adjunctive Study of AL-37807 Ophthalmic Suspension

NCT00620256
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
AL-37807 ophthalmic suspension, 0.1%, Timolol gel forming solution, 0.5%, AL-37807 ophthalmic solution vehicle, Latanoprost ophthalmic solution
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Oct 8, 2026, 11:56 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

NCT00332436
View directory record Official record
Conditions
Ocular Hypertension
Interventions
brimonidine/timolol fixed combination
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Oct 8, 2026, 11:56 AM EDT
Completed Phase 3 Interventional Results available

DE-117 Spectrum 5 Study

NCT03697811
View directory record Official record
Conditions
Primary Open-angle Glaucoma and Ocular Hypertension
Interventions
DE-117 Ophthalmic Solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
32
States / cities
Chandler, Arizona • Glendale, California • Mission Hills, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 8, 2026, 11:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Caffeinated Coffee on Intraocular Pressure

NCT01364207
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Caffeinated Coffee, Decaffeinated Coffee
Other
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
40 Years to 89 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Oct 8, 2026, 11:56 AM EDT
Completed Not applicable Interventional

Confronting Unequal Eye Care in Pennsylvania

NCT01179555
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetes Mellitus, Type 2, Glaucoma
Interventions
Behavioral Activation, Supportive Therapy
Behavioral
Lead sponsor
Wills Eye
Other
Eligibility
21 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 8, 2026, 11:56 AM EDT
Completed No phase listed Observational

Diurnal and Nocturnal Effect of Travatan With SofZia Preservative on Intraocular Pressure and Ocular Perfusion Pressure

NCT01779778
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 2, 2016 · Synced Oct 8, 2026, 11:56 AM EDT